11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA)

11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA)

[!NOTE] Paradigm Shift in Diabetic Pharmacotherapy: Modern management of Type 2 diabetes in cardiovascular populations has transitioned from a glucose-centric glucocentric model to an organ-protective cardiorenal risk reduction model. Beyond lowering $HbA_{1c}$, current American Diabetes Association (ADA) and American College of Cardiology (ACC) guidelines prioritize agents with proven reductions in Major Adverse Cardiovascular Events (MACE), cardiovascular mortality, and heart failure hospitalizations—specifically SGLT2 inhibitors and GLP-1 receptor agonists.

Secondary prevention clinicians in cardiac rehabilitation routinely supervise patients prescribed multi-drug antidiabetic regimens. Understanding medication mechanisms, pharmacokinetic half-lives, renal clearance cutoffs, and exercise-specific adverse effect profiles is essential to preserve hemodynamic stability and prevent acute exercise-related metabolic crises.

---

1. Biguanides: Metformin

Metformin remains the initial first-line oral antidiabetic pharmacotherapy for most patients with Type 2 diabetes.

Mechanism of Action & Hemodynamics

• Molecular Target: Metformin acts primarily through the activation of AMP-activated protein kinase (AMPK) within hepatocytes and skeletal myocytes, while mildly inhibiting complex I of the mitochondrial respiratory chain.
• Physiological Effects: It suppresses hepatic gluconeogenesis and glycogenolysis, increases peripheral skeletal muscle insulin sensitivity (enhancing GLUT4 translocation), and modestly slows intestinal glucose absorption.
• Hypoglycemia Risk: Negligible as monotherapy. Because metformin does not stimulate pancreatic $\beta$-cell insulin exocytosis, it does not induce acute hypoglycemia during aerobic or resistance training.
• Weight & Lipid Effects: Weight-neutral or induces modest weight reduction (1–3 kg). Modestly reduces plasma triglycerides and low-density lipoprotein cholesterol (LDL-C).

Clinical Precautions & Renal Thresholds

• Gastrointestinal Symptoms: Diarrhea, nausea, abdominal cramping, and flatulence occur in up to 20% to 30% of patients, typically mitigated by extended-release formulations and slow dose titration with meals.
• Lactic Acidosis Risk: A rare ($~3\text{ to }9\text{ cases per }100,000\text{ patient-years}$) but life-threatening metabolic complication (mortality $>30%$) resulting from mitochondrial lactate clearance inhibition.
• Renal Function Thresholds (eGFR):
  • $\text{eGFR} \ge 45\text{ mL/min/1.73m}^2$: Full dosing permitted (up to $2,000\text{--}2,550\text{ mg/day}$).
  • $\text{eGFR } 30\text{--}44\text{ mL/min/1.73m}^2$: Do not initiate new therapy; if already taking metformin, reduce maximum dose by 50% (maximum $1,000\text{ mg/day}$) and monitor renal function every 3 months.
  • $\text{eGFR} < 30\text{ mL/min/1.73m}^2$: Absolute contraindication; discontinue drug immediately.
• Radiocontrast & Perioperative Holds: Withhold metformin at the time of or prior to iodinated contrast procedures (coronary angiography, CT scans) and in acute hypoxic or shock states; resume after 48 hours only if renal function remains stable.
• Vitamin $B_{12}$ Deficiency: Long-term use impairs ileal absorption of vitamin $B_{12}$ in 10% to 15% of patients, potentially mimicking or worsening peripheral neuropathy. Annual monitoring of serum $B_{12}$ is recommended.

---

2. Insulin Secretagogues: Sulfonylureas & Meglitinides

Insulin secretagogues augment endogenous insulin secretion by directly targeting pancreatic $\beta$-cells.

Mechanism of Action: The Glucose-Independent Hazard

• Molecular Target: Sulfonylureas (glipizide, glimepiride, glyburide) and meglitinides (repaglinide, nateglinide) bind to the sulfonylurea receptor 1 (SUR1) regulatory subunit of ATP-sensitive potassium ($K_{ATP}$) channels on the $\beta$-cell membrane.
• Cellular Cascade: Channel closure $\rightarrow$ cell membrane depolarization $\rightarrow$ opening of voltage-gated L-type calcium channels $\rightarrow$ intracellular calcium influx $\rightarrow$ exocytosis of preformed insulin granules.
• The Exercise Problem: Crucially, this secretory cascade occurs independently of ambient blood glucose concentrations. During physical exercise, skeletal muscle contraction stimulates insulin-independent GLUT4 translocation. When combined with pharmacologically unsuppressed insulin secretion from sulfonylureas, circulating glucose is cleared rapidly while hepatic glucose output is blocked, creating a profound risk of severe, prolonged exercise-induced hypoglycemia.
• Agent Selection: Glyburide possesses active circulating metabolites that accumulate in renal impairment and is contraindicated in the elderly and patients with CKD. Glipizide (short half-life, inactive liver metabolites) and glimepiride are preferred if a secretagogue must be utilized.
• Meglitinides: Rapid-onset, short-acting secretagogues taken 15 to 30 minutes before meals to target postprandial spikes. While having a shorter window of hypoglycemia risk than sulfonylureas, they still cause hypoglycemia if exercise is performed in the early postprandial window.

---

3. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

SGLT2 inhibitors have transformed cardiorenal risk management in secondary prevention.

Mechanism & Cardiorenal Hemodynamics

• Agents: Empagliflozin, dapagliflozin, canagliflozin.
• Renal Mechanism: SGLT2 is a high-capacity, low-affinity transporter located in the S1/S2 segment of the renal proximal convoluted tubule responsible for reabsorbing ~90% of filtered glucose. SGLT2 inhibitors block this transporter, promoting urinary glucose excretion (glucosuria of $70\text{--}100\text{ g/day}$, equivalent to caloric loss of $280\text{--}400\text{ kcal/day}$) and modest natriuresis.
• Cardiorenal Benefits: Groundbreaking cardiovascular outcome trials (EMPA-REG OUTCOME, DAPA-HF, DELIVER, EMPEROR-Reduced, EMPEROR-Preserved) demonstrated:
  • 25% to 35% reduction in heart failure hospitalizations across both HFrEF and HFpEF, regardless of diabetes status.
  • Significant reduction in cardiovascular death and all-cause mortality.
  • Slowed progression of chronic kidney disease (attenuation of eGFR decline and reduction in end-stage renal disease).
  • Mild reduction in systolic blood pressure ($3\text{--}5\text{ mmHg}$) and modest weight loss ($2\text{--}3\text{ kg}$).
• Guideline Status: Class 1A recommendation from ACC, AHA, and ESC for all patients with heart failure (HFrEF and HFpEF) and diabetic kidney disease.

Clinical & Exercise Safety Concerns in CR

1. Hypovolemia and Orthostatic Hypotension: Osmotic diuresis reduces plasma volume by ~7%. When combined with loop diuretics (furosemide, bumetanide) and antihypertensives in cardiac rehab, patients are vulnerable to volume depletion, post-exercise presyncope, and orthostatic blood pressure drops. Diuretic doses frequently require downward adjustment.
2. Euglycemic Diabetic Ketoacidosis (euDKA): SGLT2 inhibitors lower plasma glucose while stimulating glucagon release and promoting lipid oxidation. This can precipitate severe ketoacidosis accompanied by paradoxically near-normal blood glucose levels ($< 250\text{ mg/dL}$). Precipitants include prolonged strenuous endurance exercise, severe dehydration, acute illness, infection, perioperative fasting, or low-carbohydrate/ketogenic diets. Exercise must be withheld if ketones are elevated regardless of glucose level.
3. Mycotic Genital Infections & UTIs: Elevated urinary glucose levels increase the risk of vulvovaginal candidiasis and fungal balanitis; rare reports of necrotizing fasciitis of the perineum (Fournier gangrene).

---

4. Incretin-Based Therapies: GLP-1 Receptor Agonists & GIP/GLP-1 Co-Agonists

Glucagon-Like Peptide-1 (GLP-1) receptor agonists provide profound metabolic and anti-atherosclerotic benefits.

Mechanism of Action & Vascular Efficacy

• Agents: Semaglutide (subcutaneous weekly or oral daily), liraglutide (subcutaneous daily), dulaglutide (subcutaneous weekly); and the dual GIP/GLP-1 receptor agonist tirzepatide.
• Incretin Biology: Incretins are gut-derived peptide hormones released in response to nutrient ingestion. Native GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1 receptor agonists are synthetic analogs resistant to DPP-4 breakdown.
• Physiological Actions:
  • Glucose-Dependent Insulin Release: Stimulate $\beta$-cell insulin exocytosis only when blood glucose concentrations are elevated above fasting levels ($> 90\text{ mg/dL}$), resulting in minimal intrinsic hypoglycemia risk as monotherapy.
  • Glucagon Suppression: Attenuate postprandial hyperglucagonemia.
  • Gastric Motility Slowing: Delay gastric emptying, blunting postprandial glucose excursions.
  • Hypothalamic Satiety Induction: Suppress appetite, yielding substantial weight loss ($5%\text{--}15%+$ total body weight; up to $20%+$ with tirzepatide).
• Cardiovascular Protection: Trials including LEADER (liraglutide), SUSTAIN-6 (semaglutide), and SELECT (semaglutide in overweight/obese CVD patients without diabetes) demonstrated significant 12% to 26% reductions in 3-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke).
• Heart Failure with Preserved Ejection Fraction (HFpEF): The STEP-HFpEF trials demonstrated that semaglutide produced substantial improvements in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary scores, 6-minute walk distance, and weight loss in patients with obesity-related HFpEF.

Clinical & Exercise Safety Considerations in CR

• Gastrointestinal Effects: Nausea, vomiting, diarrhea, and constipation occur in 25% to 40% of patients during dose escalation. Delayed gastric emptying can alter the digestion kinetics of pre-exercise carbohydrate snacks.
• Hypoglycemia Risk: Although low as monotherapy, when combined with basal/bolus insulin or sulfonylureas, the background secretagogue/insulin dose must be proactively reduced (by 20% to 50%) upon initiating GLP-1 RAs to prevent exercise-induced hypoglycemia.

---

5. Other Oral Classes: DPP-4 Inhibitors & Thiazolidinediones

• DPP-4 Inhibitors (Gliptins: sitagliptin, linagliptin, saxagliptin): Inhibit the degradation of endogenous incretins; weight neutral with very low hypoglycemia risk. Heart Failure Caution: Saxagliptin significantly increased heart failure hospitalizations in the SAVOR-TIMI 53 trial and is avoided in heart failure.
• Thiazolidinediones (TZDs: pioglitazone): PPAR-$\gamma$ agonists that enhance peripheral insulin sensitivity in muscle and adipose tissue. Black Box Warning: TZDs cause renal sodium and fluid retention, precipitating or worsening congestive heart failure. They are absolutely contraindicated in patients with NYHA Class III or IV heart failure.

---

6. Exogenous Insulin Regimens & Exercise Absorption Kinetics

Patients with Type 1 diabetes and long-standing Type 2 diabetes rely on exogenous insulin regimens:

The Critical Exercise Injection Site Rule

A vital patient safety rule in cardiac rehabilitation governs the anatomical site of insulin injection:

• The Physiological Hazard: Subcutaneous microvascular blood flow to actively exercising skeletal muscle increases dramatically (exertional hyperemia) to satisfy metabolic oxygen demands.
• The Clinical Consequence: If a patient injects rapid- or short-acting insulin into subcutaneous tissue overlying an active muscle bed (e.g., injecting into the anterior thigh prior to treadmill walking, jogging, or stationary cycling), the accelerated regional perfusion drastically speeds insulin dissolution and systemic vascular absorption.
• The Adverse Outcome: This creates an unexpected, premature hyperinsulinemic spike precisely during peak exercise exertion, triggering acute, severe hypoglycemia.
• Mandatory Clinical Directive: Patients must be instructed to avoid injecting insulin into exercising muscle groups. Injections should be administered into the abdominal wall (rotating periumbilical sites) or non-exercising anatomical regions at least 1 hour prior to exercise sessions.

---

Comprehensive Antidiabetic Pharmacotherapy Reference Table

---

Realistic Clinical Scenario: Medication Optimization & Presyncope Evaluation

Clinical Scenario: A 65-year-old male with Type 2 diabetes and ischemic cardiomyopathy (LVEF 30%, NYHA Class II) enrolled in Phase II cardiac rehabilitation following coronary artery bypass graft surgery (CABG $\times 3$). His current medication regimen includes glimepiride $4\text{ mg}$ daily, metformin $1,000\text{ mg}$ twice daily, carvedilol $25\text{ mg}$ twice daily, sacubitril/valsartan $49/51\text{ mg}$ twice daily, and furosemide $40\text{ mg}$ daily. During session 4, 25 minutes into treadmill ambulation, the patient develops diaphoresis, lightheadedness, and profound presyncope. Immediate evaluation reveals: heart rate $68\text{ bpm}$, blood pressure $92/58\text{ mmHg}$, and fingerstick capillary glucose $54\text{ mg/dL}$.

Clinical Management & Pharmacotherapy Redesign:

1. Acute Resuscitation: Exercise is immediately halted; 15g rapid-acting glucose gel is administered, and the Rule of 15 is executed, raising glucose to $104\text{ mg/dL}$ at 15 minutes.
2. Pharmacologic Root Cause Analysis: The combination of unsuppressed insulin secretion from high-dose glimepiride and exertional GLUT4 translocation precipitated severe exercise-induced hypoglycemia. Concurrently, loop diuresis and dual neurohormonal blockade exacerbated exertional hypotension.
3. Guideline-Directed Medical Optimization: The CR medical director contacts the cardiologist and primary physician. In accordance with ADA/ACC guidelines, glimepiride is completely discontinued. The patient is initiated on empagliflozin $10\text{ mg}$ daily (providing Class 1A mortality and HF hospitalization reduction for his HFrEF) and subcutaneous semaglutide $0.25\text{ mg}$ weekly (targeting weight loss and MACE reduction). Furosemide is reduced to $20\text{ mg}$ daily to mitigate hypovolemia. Over the subsequent 8 weeks, the patient completes rehabilitation without recurrent hypoglycemia or presyncope.